Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

1. Ubrogepant (Ubrelvy) - acute treatment of migraine with or without aura in adults

Ubrogepant (Ubrelvy) - acute treatment of migraine with or without aura in adults Drug Approval Package: UBRELVY UBRELVY " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: UBRELVY Company: Allergan Sales, Inc. Application Number: 211765 Approval Date: 12/23/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files

2020 FDA - Drug Approval Package

2. Vascular safety of erenumab for migraine prevention Full Text available with Trip Pro

Vascular safety of erenumab for migraine prevention Vascular Safety of Erenumab for Migraine Prevention - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S. National Library of Medicine National Center for Biotechnology Information Show account info (...) to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Neurology Actions 2019 Dec 18 [Online ahead of print] Vascular Safety of Erenumab for Migraine Prevention , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 From California Medical Clinic for Headache (D.K.), Santa Monica, CA; Department of Neurology (J.P.), University Hospital Marqués de Valdecilla and IDIVAL, Santander, Spain; Premiere Research Institute (P.K.W.), Nova Southeastern University, West Palm Beach, FL

2020 EvidenceUpdates

3. Galcanezumab (Emgality) - migraine

Galcanezumab (Emgality) - migraine Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012 will be updated

2020 Health Canada - Drug and Health Product Register

4. Fremanezumab (Ajovy) - chronic and episodic migraine

Fremanezumab (Ajovy) - chronic and episodic migraine 1 Published 13 January 2020 1 SMC2226 fremanezumab 225mg solution for injection in pre- filled syringe (Ajovy®) Teva UK Limited 6 December 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission fremanezumab (Ajovy ® ) is accepted (...) for restricted use within NHSScotland. Indication under review: For prophylaxis of migraine in adults who have at least four migraine days per month. SMC restriction: for the treatment of patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments. Three phase III studies demonstrated superiority of fremanezumab over placebo in reducing the number of monthly migraine days in patients with chronic and episodic migraine. This advice applies only

2020 Scottish Medicines Consortium

5. Acute Treatments for Migraine

Acute Treatments for Migraine ©Institute for Clinical and Economic Review, 2020 Acute Treatments for Migraine Evidence Report January 10, 2020 Prepared for ©Institute for Clinical and Economic Review, 2020 Page i Evidence Report- Acute Treatments for Migraine ICER Staff and Consultants The University of Illinois at Chicago College of Pharmacy’s Center for Pharmacoepidemiology and Pharmacoeconomic Research* Steven J. Atlas, MD, MPH Associate Professor of Medicine Harvard Medical School, Boston (...) , and the resulting ICER reports do not necessarily represent the views of the UIC. DATE OF PUBLICATION: January 10, 2020 How to cite this document: Atlas S, Touchette D, Agboola F, Lee T, Chapman R, Pearson S D, Rind D M. Acute Treatments for Migraine: Effectiveness and Value. Institute for Clinical and Economic Review, January 8,2020. http://icer-review.org/material/acute-migraine-evidence-report/ Steven Atlas served as the lead author for the report. Foluso Agboola led the systematic review and authorship

2020 California Technology Assessment Forum

6. Efficacy of levetiracetam for migraine prophylaxis: a systematic review and meta-analysis of randomized control trials

Efficacy of levetiracetam for migraine prophylaxis: a systematic review and meta-analysis of randomized control trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

7. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2020 PROSPERO

8. Auricular therapy for migraine attacks in adults: a systematic review and meta-analysis

Auricular therapy for migraine attacks in adults: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2020 PROSPERO

9. Propofol for Treatment of Acute Migraine in the Emergency Department: A Systematic Review (Abstract)

Propofol for Treatment of Acute Migraine in the Emergency Department: A Systematic Review Propofol has not been extensively studied as an acute migraine therapy; however, based on the limited evidence from outpatient and inpatient settings, propofol has been proposed as an option for patients who present to the emergency department (ED). The purpose of this review was to evaluate the existing literature regarding the safety and efficacy of propofol for acute migraine treatment in the ED.A (...) systematic review of clinical studies of propofol treatment for acute migraine in the ED was performed using Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. Trials were identified through PubMed, Google Scholar, clinical trial registries, research registries, and key journals through May 2019. A modified Jadad scoring system was used to assess the methodologic quality of the included randomized controlled trials, and the Newcastle-Ottawa Scale was used

2019 EvidenceUpdates

10. Lasmiditan (Reyvow) - For the acute treatment of migraine with or without aura, in adults

Lasmiditan (Reyvow) - For the acute treatment of migraine with or without aura, in adults Drug Approval Package: REYVOW (lasmitidan) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: REYVOW (lasmitidan) Company: Eli Lilly Application Number: 211280 Orig 1 Approval Date: 10/11/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2019 FDA - Drug Approval Package

11. Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V

Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.7 of the dossier assessment Galcanezumab (Migräne) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-28 Galcanezumab (migraine (...) ) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-28 Version 1.0 Galcanezumab (migraine) 27 June 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Galcanezumab (migraine) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 29 March 2019 Internal Commission No.: A19-28 Address

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

12. Acupuncture for migraine headaches

Acupuncture for migraine headaches Acupuncture for migraine headaches Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Acupuncture for migraine headaches View/ Open Date 2010-04 Format Metadata Abstract Acupuncture reduces the frequency of migraine headaches when used as an adjunct to, or in place of, medical management

2019 Clinical Inquiries

13. Erenumab (Aimovig) - Migraine

Erenumab (Aimovig) - Migraine erenumab | CADTH.ca Find the information you need erenumab erenumab Last Updated: October 3, 2019 Result type: Reports Project Number: SR0578-000 Product Line: Generic Name: erenumab Brand Name: Aimovig Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: Migraine Manufacturer Requested Reimbursement Criteria 1 : For prevention of migraine in adults who have at least 8 migraine days per month and who have previously failed, are intolerant, or have (...) a contraindication to at least two migraine preventive therapies Submission Type: New Project Status: Active Biosimilar: No Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable. Key Milestones 2 Call for patient input posted April 04, 2019 Clarification: CADTH initially posted the call for patient from July 12, 2018 to August 31

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

14. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. (Abstract)

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor have shown efficacy in the prevention of migraine attacks. We investigated the efficacy and tolerability of fremanezumab, a fully humanised CGRP antibody, in patients with migraine who had previously (...) not responded to two to four classes of migraine preventive medications.The randomised, double-blind, placebo-controlled, parallel-group, phase 3b FOCUS trial was done at 104 sites (including hospitals, medical centres, research institutes, and group practice clinics) across Belgium, the Czech Republic, Denmark, Finland, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, Switzerland, the UK, and the USA. We enrolled participants aged 18-70 years with episodic or chronic migraine who had

2019 Lancet Controlled trial quality: predicted high

15. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society Full Text available with Trip Pro

Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society To provide evidence-based recommendations for the acute symptomatic treatment of children and adolescents with migraine.We performed a systematic review of the literature and rated risk of bias of included studies according to the American Academy (...) , acetaminophen (in children and adolescents), and triptans (mainly in adolescents) for the relief of migraine pain, although confidence in the evidence varies between agents. There is high confidence that adolescents receiving oral sumatriptan/naproxen and zolmitriptan nasal spray are more likely to be headache-free at 2 hours than those receiving placebo. No acute treatments were effective for migraine-related nausea or vomiting; some triptans were effective for migraine-related phonophobia

2019 EvidenceUpdates

16. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society Full Text available with Trip Pro

Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society To provide updated evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population.The authors systematically reviewed literature from January 2003 (...) to August 2017 and developed practice recommendations using the American Academy of Neurology 2011 process, as amended.Fifteen Class I-III studies on migraine prevention in children and adolescents met inclusion criteria. There is insufficient evidence to determine if children and adolescents receiving divalproex, onabotulinumtoxinA, amitriptyline, nimodipine, or flunarizine are more or less likely than those receiving placebo to have a reduction in headache frequency. Children with migraine receiving

2019 EvidenceUpdates

17. Erenumab (Aimovig) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects

Erenumab (Aimovig) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects Prescrire IN ENGLISH - Spotlight ''Erenumab (Aimovig°) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects '', 1 September 2019 {1} {1} {1} | | Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Erenumab (Aimovig°) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects FEATURED REVIEW Erenumab (Aimovig°) is a monoclonal antibody that has been authorised in the European Union for the prevention of migraine attacks in patients who experience attacks on more than 4 days a month. Prescrire's editorial staff have weighed

2019 Prescrire

18. Erenumab (Aimovig) for the prophylaxis of adults with migraine

Erenumab (Aimovig) for the prophylaxis of adults with migraine WAR-report (summary) 2019043968 www.zinl.nl Erenumab (Aimovig ® ) for the prophylaxis of adults with migraine Summary of recommendations by Zorginstituut Nederland (National Health Care Institute, the Netherlands) dated 27 June 2019 Zorginstituut Nederland carried out an assessment of the medicinal product erenumab (Aimovig ® ) and came to the following conclusion. In a letter dated 12 November 2018 (CIBG-18-072 11), the Minister (...) of Health, Welfare and Sport (VWS) asked Zorginstituut Nederland to perform a substantive assessment of whether the medicinal product erenumab (Aimovig ® ) is interchangeable with any product included in the insured package. The Zorginstituut has completed its assessment. Their considerations are to be found in the GVS report that was sent to the Minister. Registered indication The full registered indication is as follows: “Erenumab is indicated for the prophylaxis of migraine in adults who have

2019 National Health Care Institute (Zorginstituut Nederland)

19. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. (Abstract)

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Rimegepant, a small molecule calcitonin gene-related peptide receptor antagonist, has shown efficacy in the acute treatment of migraine using a standard tablet formulation. The objective of this trial was to compare the efficacy, safety, and tolerability of a novel orally disintegrating tablet formulation of rimegepant (...) at 75 mg with placebo in the acute treatment of migraine.In this double-blind, randomised, placebo-controlled, multicentre phase 3 trial, adults aged 18 years or older with history of migraine of at least 1 year were recruited to 69 study centres in the USA. Participants were randomly assigned to receive rimegepant (75 mg orally disintegrating tablet) or placebo and instructed to treat a single migraine attack of moderate or severe pain intensity. The randomisation was stratified by the use

2019 Lancet Controlled trial quality: predicted high

20. Pharmacologic Treatment for Pediatric Migraine Prevention

Pharmacologic Treatment for Pediatric Migraine Prevention 1 Practice guideline update: 1 Pharmacologic treatment for pediatric migraine prevention 2 Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the 3 American Academy of Neurology and the American Headache Society 4 Authors 5 Maryam Oskoui, MD, MSc, 1 Tamara Pringsheim, MD, 2 Lori Billinghurst MD, 3 Sonja Potrebic, 6 MD, PhD, 4 Elaine M. Gersz, 5 David Gloss, MD, MPH&TM, 6 Yolanda Holler-Managan, MD, 7 7 (...) with Episodic or Chronic Migraine: Effectiveness and Value Final Evidence Report. 2 3 L. Billinghurst has no relevant disclosures for this guideline. D. Gloss has no relevant disclosures 4 for this guideline. 5 A. Hershey has served on a scientific advisory board for Allergan, XOC Pharma, and Amgen; 6 served as an editor for Headache, Cephalalgia, and the Journal of Headache and Pain; has 7 received compensation from Allergan and MAP Pharma and currently receives compensation 8 from Alder, Amgen, Avanir

2019 American Academy of Neurology